ISRCTN74716448 https://doi.org/10.1186/ISRCTN74716448

An open label, randomised comparative study of supervised and unsupervised amodiaquine plus artesunate treatment for acute uncomplicated Plasmodium falciparum malaria in the Kassena Nankana District of Ghana

Submission date
20/08/2007

Recruitment status
No longer recruiting

Registration date
29/02/2008

Overall study status
Completed

Last Edited
31/05/2019

Condition category
Infections and Infestations

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Abraham Oduro

Contact details
Navrongo Health Research Centre (NHRC)
Post office box 114
Navrongo
Ghana
-

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Protocol serial number
2004/GD/46

Study information

Scientific Title
An open label, randomised comparative study of supervised and unsupervised amodiaquine plus artesunate treatment for acute uncomplicated Plasmodium falciparum malaria in the Kassena Nankana District of Ghana

Acronym
ASAQ

Study objectives
To compare treatment outcomes (clinical and parasitological) in patients with acute uncomplicated falciparum malaria treated with amodiaquine plus artesunate under a supervised and unsupervised regimens.

Ethics approval required
Old ethics approval format

Ethics approval(s)
1. Navrongo Health Research Centre Institutional Review Board. Date of approval: 26 October 2005 (ref: NHRCIRB038)
2. Ghana Health Service Ethical Review Committee. Date of approval: 30 June 2005 (ref: GHS-ERC-05/6/05)

Study design
Open-label randomized design.

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Acute malaria

Interventions
Supervised group: Each administration of artesuante and amaodiaquine will be supervised by a health professional
Unsupervised group: The participants will receive the first dose as above, but are given the reminder of the drugs for home administration

The doses are:
Artesunate (oral): 4 mg/Kilogram body weight daily for 3 days
Amodiaquine (oral): 10 mg/Kg body weight daily for 3 days

Intervention Type
Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)
amodiaquine , artesunate

Primary outcome(s)
Adequate clinical and parasite clearance.

Timepoints of measurement: Days 2, 3, 7, 14, 21 and 28

Key secondary outcome(s))
Parasite and fever clearance times.

Timepoints of measurement: Days 2, 3, 7, 14, 21 and 28

Completion date
30/09/2007

Eligibility

Key inclusion criteria
1. Signed witnessed informed consent
2. Bodyweight >5 kg
3. P. falciparum mono-infection with parasite density of 2,000-200,000 asexual parasites per microlitre
4. Fever (axillary temperature greater than or equal to 37.5 C) and/or history of fever
5. Haemoglobin >6.0 g/dl

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
All

Total final enrolment
308

Key exclusion criteria
1. Danger signs of severe malaria
2. Severe malnutrition
3. History of allergy to drugs
4. Other underlying chronic diseases

Date of first enrolment

01/11/2005

Date of final enrolment
30/09/2007

Locations

Countries of recruitment
Ghana

Study participating centre
Navrongo Health Research Centre (NHRC)
Navrongo
Ghana
-

Sponsor information

Organisation
Ghana Health Service (Ghana)

ROR
https://ror.org/052ss8w32

Funder(s)

Funder type
Government

Funder Name
The Ghana-Netherlands Health Research Programme (HRP) for Development, Health Research Unit, Ghana Health Service (Ghana)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2008	31/05/2019	Yes	No